Nonetheless, TKIs are considered high‐cost drugs for low‐middle income countries, and only first‐generation TKIs (erlotinib/gefitinib) are supported by the Brazilian public health system for EGFR‐mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.